Key result
Hypertension emerges as a metabolic and vascular disease linked to cardiometabolic syndrome and RAAS activation.
Highlights the paradigm shift of viewing hypertension as both a metabolic and vascular disease linked to the cardiometabolic syndrome.
May support integrated cardiometabolic hypertension care; leaves open outcome impact without prospective trials.
Hypertension and cardiovascular disease are leading causes of morbidity and mortality. Accumulating data demonstrate a relationship between hypertension and several vascular and metabolic abnormalities that are components of the cardiometabolic syndrome. The components of the cardiometabolic syndrome include insulin resistance/hyperinsulinemia, central obesity, dyslipidemia, hypertension, microalbuminuria, increased inflammation, and oxidative stress. There is growing evidence that tissue activation of the renin-angiotensin-aldosterone system participates in endothelial dysfunction, microalbuminuria, insulin resistance, and subsequent cardiovascular and chronic kidney disease. The notion that hypertension is a metabolic as well as a vascular disease opens a new paradigm for the treatment of this disorder.
No takes yet. Share an insight, caveat, or question.
Manrique et al. (2005) conducted a review in Hypertension and Cardiometabolic Syndrome. Hypertension is increasingly recognized as both a metabolic and vascular disease, linked to cardiometabolic syndrome components and renin-angiotensin-aldosterone system activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: